Ontology highlight
ABSTRACT: Background
Major depressive disorder (MDD) and treatment-resistant depression (TRD) represent a global source of societal and health burden. To advise proper management of inflammation-related depression among TRD patients, it is important to identify therapeutic clinical treatments. A key factor is related to proinflammatory cytokines such as interleukin- (IL-) 1β, IL-6, and tumor necrosis factor- (TNF-) α which have been implicated in the pathogenesis of depressive symptoms in MDD patients. Ketamine may provide an anti-inflammatory therapeutic strategy by targeting proinflammatory pathways associated with depressive disorders, which may be exacerbated in the ageing population with TRD.Objective
Despite a burgeoning body of literature demonstrating that infla
SUBMITTER: Sukhram SD
PROVIDER: S-EPMC9507757 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature